Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Arthritis and Rheumatology - United Kingdom
doi 10.1002/art.40841
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Baricitinib: A New Oral Treatment for Rheumatoid Arthritis

Prescriber
Pharmacology
2017English

Safety Profile of Baricitinib in Patients With Active Rheumatoid Arthritis With Over 2 Years Median Time in Treatment

Journal of Rheumatology
RheumatologyAllergyImmunology
2019English

Evaluation of Hepatitis B Virus in Clinical Trials of Baricitinib in Rheumatoid Arthritis

RMD Open
RheumatologyAllergyImmunology
2020English

Rheumatoid Arthritis and Cardiovascular Disease

Current Opinion in Rheumatology
Rheumatology
2013English

Safety of Rituximab in Rheumatoid Arthritis

Reumatismo
Rheumatology
2011English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2019English

Treatment of Rheumatoid Arthritis With ATP

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1949English

Mean Cost Per Number Needed to Treat of Baricitinib Versus Adalimumab in the Treatment of Rheumatoid Arthritis in Italy

Global and Regional Health Technology Assessment
Health Policy
2018English

Cardiovascular Co-Morbidity in Patients With Rheumatoid Arthritis: A Narrative Review of Risk Factors, Cardiovascular Risk Assessment and Treatment

BMC Rheumatology
Rheumatology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy